Factor XI and XII as antithrombotic targets

Arterial and venous thrombosis are major causes of morbidity and mortality, and the incidence of thromboembolic diseases increases as a population ages. Thrombi are formed by activated platelets and fibrin. The latter is a product of the plasma coagulation system. Currently available anticoagulants...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Current opinion in hematology Ročník 18; číslo 5; s. 349
Hlavní autori:	Müller, Felicitas, Gailani, David, Renné, Thomas
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.09.2011
Predmet:	Animals Anticoagulants - pharmacology Anticoagulants - therapeutic use Blood Coagulation - drug effects Blood Coagulation - physiology Factor XI - antagonists & inhibitors Factor XI - metabolism Factor XI Deficiency - blood Factor XI Deficiency - drug therapy Factor XI Deficiency - metabolism Factor XII - antagonists & inhibitors Factor XII - metabolism Factor XII Deficiency - blood Factor XII Deficiency - drug therapy Factor XII Deficiency - metabolism Hemostasis - drug effects Hemostasis - physiology Humans Thrombosis - drug therapy Thrombosis - metabolism
ISSN:	1531-7048, 1531-7048
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Arterial and venous thrombosis are major causes of morbidity and mortality, and the incidence of thromboembolic diseases increases as a population ages. Thrombi are formed by activated platelets and fibrin. The latter is a product of the plasma coagulation system. Currently available anticoagulants such as heparins, vitamin K antagonists and inhibitors of thrombin or factor Xa target enzymes of the coagulation cascade that are critical for fibrin formation. However, fibrin is also necessary for terminating blood loss at sites of vascular injury. As a result, anticoagulants currently in clinical use increase the risk of bleeding, partially offsetting the benefits of reduced thrombosis. This review focuses on new targets for anticoagulation that are associated with minimal or no therapy-associated increased bleeding. Data from experimental models using mice and clinical studies of patients with hereditary deficiencies of coagulation factors XI or XII have shown that both of these clotting factors are important for thrombosis, while having minor or no apparent roles in processes that terminate blood loss (hemostasis). Hereditary deficiency of factor XII (Hageman factor) or factor XI, plasma proteases that initiate the intrinsic pathway of coagulation, impairs thrombus formation and provides protection from vascular occlusive events, while having a minimal impact on hemostasis. As the factor XII-factor XI pathway contributes to thrombus formation to a greater extent than to normal hemostasis, pharmacological inhibition of these coagulation factors may offer the exciting possibility of anticoagulation therapies with minimal or no bleeding risk.
AbstractList	Arterial and venous thrombosis are major causes of morbidity and mortality, and the incidence of thromboembolic diseases increases as a population ages. Thrombi are formed by activated platelets and fibrin. The latter is a product of the plasma coagulation system. Currently available anticoagulants such as heparins, vitamin K antagonists and inhibitors of thrombin or factor Xa target enzymes of the coagulation cascade that are critical for fibrin formation. However, fibrin is also necessary for terminating blood loss at sites of vascular injury. As a result, anticoagulants currently in clinical use increase the risk of bleeding, partially offsetting the benefits of reduced thrombosis. This review focuses on new targets for anticoagulation that are associated with minimal or no therapy-associated increased bleeding.PURPOSE OF REVIEWArterial and venous thrombosis are major causes of morbidity and mortality, and the incidence of thromboembolic diseases increases as a population ages. Thrombi are formed by activated platelets and fibrin. The latter is a product of the plasma coagulation system. Currently available anticoagulants such as heparins, vitamin K antagonists and inhibitors of thrombin or factor Xa target enzymes of the coagulation cascade that are critical for fibrin formation. However, fibrin is also necessary for terminating blood loss at sites of vascular injury. As a result, anticoagulants currently in clinical use increase the risk of bleeding, partially offsetting the benefits of reduced thrombosis. This review focuses on new targets for anticoagulation that are associated with minimal or no therapy-associated increased bleeding.Data from experimental models using mice and clinical studies of patients with hereditary deficiencies of coagulation factors XI or XII have shown that both of these clotting factors are important for thrombosis, while having minor or no apparent roles in processes that terminate blood loss (hemostasis).RECENT FINDINGSData from experimental models using mice and clinical studies of patients with hereditary deficiencies of coagulation factors XI or XII have shown that both of these clotting factors are important for thrombosis, while having minor or no apparent roles in processes that terminate blood loss (hemostasis).Hereditary deficiency of factor XII (Hageman factor) or factor XI, plasma proteases that initiate the intrinsic pathway of coagulation, impairs thrombus formation and provides protection from vascular occlusive events, while having a minimal impact on hemostasis. As the factor XII-factor XI pathway contributes to thrombus formation to a greater extent than to normal hemostasis, pharmacological inhibition of these coagulation factors may offer the exciting possibility of anticoagulation therapies with minimal or no bleeding risk.SUMMARYHereditary deficiency of factor XII (Hageman factor) or factor XI, plasma proteases that initiate the intrinsic pathway of coagulation, impairs thrombus formation and provides protection from vascular occlusive events, while having a minimal impact on hemostasis. As the factor XII-factor XI pathway contributes to thrombus formation to a greater extent than to normal hemostasis, pharmacological inhibition of these coagulation factors may offer the exciting possibility of anticoagulation therapies with minimal or no bleeding risk. Arterial and venous thrombosis are major causes of morbidity and mortality, and the incidence of thromboembolic diseases increases as a population ages. Thrombi are formed by activated platelets and fibrin. The latter is a product of the plasma coagulation system. Currently available anticoagulants such as heparins, vitamin K antagonists and inhibitors of thrombin or factor Xa target enzymes of the coagulation cascade that are critical for fibrin formation. However, fibrin is also necessary for terminating blood loss at sites of vascular injury. As a result, anticoagulants currently in clinical use increase the risk of bleeding, partially offsetting the benefits of reduced thrombosis. This review focuses on new targets for anticoagulation that are associated with minimal or no therapy-associated increased bleeding. Data from experimental models using mice and clinical studies of patients with hereditary deficiencies of coagulation factors XI or XII have shown that both of these clotting factors are important for thrombosis, while having minor or no apparent roles in processes that terminate blood loss (hemostasis). Hereditary deficiency of factor XII (Hageman factor) or factor XI, plasma proteases that initiate the intrinsic pathway of coagulation, impairs thrombus formation and provides protection from vascular occlusive events, while having a minimal impact on hemostasis. As the factor XII-factor XI pathway contributes to thrombus formation to a greater extent than to normal hemostasis, pharmacological inhibition of these coagulation factors may offer the exciting possibility of anticoagulation therapies with minimal or no bleeding risk.
Author	Renné, Thomas Gailani, David Müller, Felicitas
Author_xml	– sequence: 1 givenname: Felicitas surname: Müller fullname: Müller, Felicitas organization: Clinical Chemistry, Department of Molecular Medicine and Surgery, Karolinska Institutet, University Hospital, Stockholm, Sweden – sequence: 2 givenname: David surname: Gailani fullname: Gailani, David – sequence: 3 givenname: Thomas surname: Renné fullname: Renné, Thomas
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/21730835$$D View this record in MEDLINE/PubMed
BookMark	eNpNkEtLw0AUhQep2If-A5HsXEjqnUcyk6WU1hYq3Si4CzeTOxrJo2YmC_-9ESu4-r7F4cA5czZpu5YYu-aw5JDp-6fDdgkFcElSGKkyTSk_YzOeSB5rUGbyz6ds7v0HABcZJBdsKriWYGQyY3cbtKHro9ddhG05YqQfNVThve-aoguVjQL2bxT8JTt3WHu6OnHBXjbr59U23h8ed6uHfWyTDHicJqVJnSpLdBkI5JaD1o4UGatQKSTpAEgUKZnCUumEK8AJqw0iV1aiWLDb395j330O5EPeVN5SXWNL3eBzY6T8uUCNyZtTcigaKvNjXzXYf-V_-8Q3QJ1UXA
CitedBy_id	crossref_primary_10_1016_j_jmgm_2019_03_019 crossref_primary_10_1016_j_thromres_2020_08_040 crossref_primary_10_1038_s41598_017_02055_x crossref_primary_10_1160_TH12_10_0772 crossref_primary_10_1186_s12896_018_0431_4 crossref_primary_10_1182_blood_2012_07_444935 crossref_primary_10_1080_09537104_2018_1428738 crossref_primary_10_1084_jem_20250049 crossref_primary_10_3390_life11101095 crossref_primary_10_1016_j_jaci_2014_07_057 crossref_primary_10_3390_jcdd9120437 crossref_primary_10_2147_VHRM_S331614 crossref_primary_10_1016_j_thromres_2014_09_030 crossref_primary_10_1371_journal_pone_0146783 crossref_primary_10_1016_j_thromres_2025_109428 crossref_primary_10_1016_j_ejmech_2016_01_023 crossref_primary_10_1517_13543784_2013_821463 crossref_primary_10_1134_S0006350917050232 crossref_primary_10_1007_s00011_018_01210_y crossref_primary_10_1016_j_bmcl_2017_06_058 crossref_primary_10_1007_s10557_025_07741_x crossref_primary_10_1038_nrdp_2015_6 crossref_primary_10_1182_blood_2014_11_611319 crossref_primary_10_1182_blood_2018_11_882993 crossref_primary_10_1016_S0049_3848_16_30363_2 crossref_primary_10_1097_MBC_0b013e328355c9cb crossref_primary_10_3390_v16020245 crossref_primary_10_3389_fcvm_2022_903029 crossref_primary_10_1160_TH12_08_0549 crossref_primary_10_1016_j_bbrc_2013_05_082 crossref_primary_10_1080_14656566_2016_1241233 crossref_primary_10_1039_D5BM00406C crossref_primary_10_1160_TH12_04_0264 crossref_primary_10_1016_j_rpth_2023_100118 crossref_primary_10_1160_TH12_07_0465 crossref_primary_10_1016_j_str_2017_12_010 crossref_primary_10_1002_rth2_12080 crossref_primary_10_1111_j_1365_2516_2012_02841_x crossref_primary_10_1160_TH12_11_0803 crossref_primary_10_24287_1726_1708_2020_19_4_243_250 crossref_primary_10_1016_S0140_6736_21_02225_X crossref_primary_10_1126_scitranslmed_aaf4331 crossref_primary_10_4103_0022_3859_105448 crossref_primary_10_1371_journal_pone_0111713 crossref_primary_10_1111_sdi_13219 crossref_primary_10_1160_TH12_11_0840 crossref_primary_10_1160_th14_04_0311 crossref_primary_10_1161_STROKEAHA_112_660340 crossref_primary_10_1016_j_bpj_2012_10_011 crossref_primary_10_1097_SHK_0000000000002362 crossref_primary_10_1160_TH13_10_0812 crossref_primary_10_3390_molecules27041234 crossref_primary_10_1159_000445854 crossref_primary_10_1080_17474086_2023_2227788 crossref_primary_10_1111_jth_12707 crossref_primary_10_1016_j_blre_2019_100615 crossref_primary_10_1161_ATVBAHA_114_304005 crossref_primary_10_1016_j_ejmech_2014_12_054 crossref_primary_10_1016_j_ibmb_2016_11_002 crossref_primary_10_3390_jcm10153383 crossref_primary_10_1160_TH13_03_0258 crossref_primary_10_3390_ph14100966 crossref_primary_10_1016_j_clinbiochem_2016_06_011 crossref_primary_10_1056_NEJMra1112830 crossref_primary_10_1016_j_thromres_2014_01_012 crossref_primary_10_1186_s12959_017_0130_8 crossref_primary_10_1016_j_drudis_2014_06_024 crossref_primary_10_3109_10409238_2015_1050550 crossref_primary_10_1160_TH13_05_0429 crossref_primary_10_1111_bjh_15872 crossref_primary_10_1038_s41467_025_62789_5 crossref_primary_10_1161_ATVBAHA_124_322145 crossref_primary_10_5482_HAMO_14_11_0060 crossref_primary_10_1111_vox_12191 crossref_primary_10_1002_minf_202200205 crossref_primary_10_1182_blood_2015_10_672766 crossref_primary_10_1016_j_jtha_2023_04_021 crossref_primary_10_1111_jth_12797 crossref_primary_10_1134_S199508022207023X crossref_primary_10_3389_fmed_2018_00066 crossref_primary_10_1160_TH15_04_0336 crossref_primary_10_1111_jth_12435 crossref_primary_10_1016_j_ijbiomac_2025_141742 crossref_primary_10_1055_s_0043_1768936 crossref_primary_10_1155_2020_2852051
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1097/MOH.0b013e3283497e61
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1531-7048
ExternalDocumentID	21730835
Genre	Research Support, Non-U.S. Gov't Journal Article Review
GrantInformation_xml	– fundername: NHLBI NIH HHS grantid: R01 HL081326 – fundername: NHLBI NIH HHS grantid: R01 HL058837
GroupedDBID	--- .-D .3C .XZ .Z2 01Q 0R~ 4Q1 4Q2 4Q3 53G 5GY 5VS 6PF 71W 8L- AAAAV AAHPQ AAIQE AAJCS AAMTA AARTV AASCR AAWTL AAYEP ABASU ABBUW ABDIG ABJNI ABVCZ ABXVJ ABXYN ABZAD ABZZY ACDDN ACEWG ACGFO ACGFS ACILI ACWDW ACWRI ACXJB ACXNZ ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEBDS AEETU AENEX AFBFQ AFDTB AFEXH AFMFG AFNMH AHQNM AHQVU AHVBC AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BQLVK BS7 C45 CAG CGR COF CS3 CUY CVF DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD EX3 F5P FCALG FL- GNXGY GQDEL H0~ HLJTE HZ~ IKREB IN~ IPNFZ JF9 JG8 JK3 JK8 K8S KD2 L-C LEELO N9A NPM N~M O9- OAG OAH OCUKA ODA ODMTH OHYEH OLC OLG OPUJH ORVUJ OUVQU OVD OVDKG OVDNE OVKID OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P R58 RIG RLZ S4R S4S T8P TEORI TSPGW V2I VVN W3M WOQ WOW X3V X3W XO3 XXN XYM YFH YOC ZFV ZZMQN 7X8 ABPXF ADKSD
ID	FETCH-LOGICAL-c5901-65d86f4ddaf902a1c1077fe4e8c4a44ae3f00e2b6e8bcedf2fb0f2c78aa14c3a2
IEDL.DBID	7X8
ISICitedReferencesCount	109
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000293780300007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1531-7048
IngestDate	Mon Sep 08 11:45:41 EDT 2025 Thu Apr 03 07:10:31 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	5
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c5901-65d86f4ddaf902a1c1077fe4e8c4a44ae3f00e2b6e8bcedf2fb0f2c78aa14c3a2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
OpenAccessLink	http://doi.org/10.1097/MOH.0b013e3283497e61
PMID	21730835
PQID	883310974
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_883310974 pubmed_primary_21730835
PublicationCentury	2000
PublicationDate	2011-September
PublicationDateYYYYMMDD	2011-09-01
PublicationDate_xml	– month: 09 year: 2011 text: 2011-September
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Current opinion in hematology
PublicationTitleAlternate	Curr Opin Hematol
PublicationYear	2011
SSID	ssj0012905
Score	2.3334165
SecondaryResourceType	review_article
Snippet	Arterial and venous thrombosis are major causes of morbidity and mortality, and the incidence of thromboembolic diseases increases as a population ages....
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	349
SubjectTerms	Animals Anticoagulants - pharmacology Anticoagulants - therapeutic use Blood Coagulation - drug effects Blood Coagulation - physiology Factor XI - antagonists & inhibitors Factor XI - metabolism Factor XI Deficiency - blood Factor XI Deficiency - drug therapy Factor XI Deficiency - metabolism Factor XII - antagonists & inhibitors Factor XII - metabolism Factor XII Deficiency - blood Factor XII Deficiency - drug therapy Factor XII Deficiency - metabolism Hemostasis - drug effects Hemostasis - physiology Humans Thrombosis - drug therapy Thrombosis - metabolism
Title	Factor XI and XII as antithrombotic targets
URI	https://www.ncbi.nlm.nih.gov/pubmed/21730835 https://www.proquest.com/docview/883310974
Volume	18
WOSCitedRecordID	wos000293780300007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV05T8MwFLaAIsTCfZRLGdhQ1MR27HhCCBEViZYOgLJFPgUDSWmA389zDpgQA0ucxVL08ux3fJ_9IXSecKpSzaAsEcSEVEY2FExTKFUUREsZq6gB2p_u-HSa5rmYddycuqNV9ntis1GbSvse-ciL4nq0lF7O30IvGuXB1U5BYxkNCGQy3ql5_gMiYNEwGGFNxyEHT-1Pzgk-mtyP-xYgxFcquGXx7zlmE2uyzX9-5Rba6JLM4Kr1im20ZMsdtDbpYPRddJE1KjtBfhvI0sAAYw2v4DnPi-pVVTAvaDni9R56zG4ersdhp5oQan-ONGSJSZmjxkgnIixjDQUed5baVFNJqbTERZHFitlUaWscdipyWPNUyphqIvE-Wimr0h6igInYUsFoRBJDnYXAlRhOLMOcKSI0HqKgt0IBXumhBlna6qMuvu0wRAetJYt5e3tGATUQ8Xnf0d-Tj9F628L1lK4TNHCwIu0pWtWf7y_14qz52_CcziZfQAKxtA
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Factor+XI+and+XII+as+antithrombotic+targets&rft.jtitle=Current+opinion+in+hematology&rft.au=M%C3%BCller%2C+Felicitas&rft.au=Gailani%2C+David&rft.au=Renn%C3%A9%2C+Thomas&rft.date=2011-09-01&rft.issn=1531-7048&rft.eissn=1531-7048&rft.volume=18&rft.issue=5&rft.spage=349&rft_id=info:doi/10.1097%2FMOH.0b013e3283497e61&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1531-7048&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1531-7048&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1531-7048&client=summon